Agilent Technologies (NYSE:A) Price Target Raised to $195.00

Agilent Technologies (NYSE:A) had its target price boosted by Barclays from $175.00 to $195.00 in a research report released on Wednesday morning,Benzinga reports. Barclays currently has an overweight rating on the medical research company’s stock.

Several other research firms also recently weighed in on A. Wall Street Zen downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Piper Sandler initiated coverage on Agilent Technologies in a research report on Thursday, June 11th. They issued a “neutral” rating and a $150.00 target price on the stock. Weiss Ratings upgraded Agilent Technologies from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, September 11th. JPMorgan Chase & Co. boosted their price target on Agilent Technologies from $180.00 to $190.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. Finally, UBS Group started coverage on Agilent Technologies in a report on Wednesday, September 9th. They issued a “neutral” rating and a $165.00 price objective on the stock. Fifteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $171.82.

Agilent Technologies Trading Up 1.5%

Agilent Technologies stock opened at $170.75 on Wednesday. The stock has a 50-day moving average of $155.85 and a two-hundred day moving average of $135.43. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.56 and a current ratio of 2.05. Agilent Technologies has a one year low of $108.35 and a one year high of $177.05. The stock has a market cap of $48.14 billion, a PE ratio of 33.61, a price-to-earnings-growth ratio of 2.56 and a beta of 1.21.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.13. Agilent Technologies had a return on equity of 24.45% and a net margin of 19.53%. The business had revenue of $1.88 billion for the quarter, compared to analyst estimates of $1.84 billion. During the same quarter in the previous year, the firm earned $1.37 earnings per share. The company’s revenue was up 8.1% on a year-over-year basis. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, research analysts anticipate that Agilent Technologies will post 6.20 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 28th. Investors of record on Tuesday, October 6th will be issued a dividend of $0.2550 per share. This represents a $1.02 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Tuesday, October 6th. Agilent Technologies’s dividend payout ratio (DPR) is 20.08%.

Insider Transactions at Agilent Technologies

In related news, Director Mikael Dolsten sold 634 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $151.38, for a total transaction of $95,974.92. Following the completion of the transaction, the director directly owned 4,924 shares in the company, valued at $745,395.12. The trade was a 11.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Hedge Funds Weigh In On Agilent Technologies

A number of institutional investors have recently modified their holdings of the stock. DKM Wealth Management Inc. acquired a new position in Agilent Technologies in the third quarter valued at approximately $258,000. Riversedge Advisors LLC boosted its position in Agilent Technologies by 28.6% in the 3rd quarter. Riversedge Advisors LLC now owns 2,043 shares of the medical research company’s stock worth $352,000 after purchasing an additional 454 shares in the last quarter. Wedmont Private Capital grew its stake in shares of Agilent Technologies by 16.7% during the 3rd quarter. Wedmont Private Capital now owns 6,533 shares of the medical research company’s stock worth $1,099,000 after purchasing an additional 934 shares during the period. LifeGoal Investments LLC acquired a new stake in shares of Agilent Technologies during the 3rd quarter worth approximately $289,000. Finally, GAMMA Investing LLC increased its holdings in shares of Agilent Technologies by 25.9% during the 3rd quarter. GAMMA Investing LLC now owns 13,016 shares of the medical research company’s stock valued at $2,243,000 after purchasing an additional 2,676 shares in the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc is an analytical measurement and laboratory technology company serving the life sciences, diagnostics, pharmaceutical, chemical, environmental, food, energy and academic research markets. Its solutions help laboratories analyze the composition, quality and performance of materials, biological samples and other substances.

The company’s products and services include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy equipment, laboratory automation tools, software, consumables and supplies.